Cargando…
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
OBJECTIVES: COVID-19 patients affected by haematological malignancies have a more severe course of the disease and higher mortality, prompting for effective prophylaxis. The present study aims to evaluate the humoral response after mRNA vaccination as well as the impact of a third vaccine dose in pa...
Autores principales: | Gressens, Simon B., Fourati, Slim, Le Bouter, Anne, Le Bras, Fabien, Dupuis, Jehan, Hammoud, Mohammad, El Gnaoui, Taoufik, Gounot, Romain, Roulin, Louise, Belhadj, Karim, Haioun, Corinne, Gallien, Sébastien, Melica, Giovanna, Lemonnier, François |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8897197/ https://www.ncbi.nlm.nih.gov/pubmed/35259530 http://dx.doi.org/10.1016/j.cmi.2022.02.029 |
Ejemplares similares
-
Anti-SARS-CoV-2 cellular response after 2 and 3 doses of BNT162b2 mRNA vaccine in lymphoma patients receiving anti-CD20 antibodies
por: Gressens, Simon B., et al.
Publicado: (2023) -
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
por: Redjoul, Rabah, et al.
Publicado: (2021) -
Antibody response after second BNT162b2 dose in allogeneic HSCT recipients
por: Redjoul, Rabah, et al.
Publicado: (2021) -
Case Report: Evolution of Humoral and Cellular Immunity in Two COVID-19 Breakthrough Infections After BNT162b2 Vaccine
por: Gallais, Floriane, et al.
Publicado: (2022) -
Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
por: Reiter, Rieke, et al.
Publicado: (2022)